medigraphic.com
ISSN 2500-7106 (Electronic)
ISSN 0123-2576 (Print)
Medicina & Laboratorio

2022, Number 3

<< Back Next >>

Medicina & Laboratorio 2022; 26 (3)

Hematological changes as a consequence of COVID-19 and its vaccines

Vizcaíno-Carruyo JC, Toro-Montoya AI

Language: Spanish
References: 58
Page: 219-236
PDF size: 472.91 Kb.


ABSTRACT

The SARS-CoV-2 virus continues to infect millions of individuals around the world. Although the most frequent symptoms observed in patients with COVID-19 are fever, fatigue and cough, in severe cases hypercoagulability and inflammation are two conditions that can cause complications and organ failure, putting the patient's life at risk. In order to classify patients during triage, different hematological markers have been explored, including platelet, lymphocyte, and eosinophil counts, and the neutrophil/lymphocyte ratio, among others. Furthermore, for the evaluation of coagulopathies, markers such as D-dimer and fibrinogen are being evaluated. This review addresses the coagulopathies and hematological parameters in pa- tients with COVID-19, as well as coagulation abnormalities such as immune thrombotic thrombocytopenia induced by SARS-CoV-2 vaccines.


REFERENCES

  1. Mendiola-Pastrana IR, López-Ortiz E, Río de laLoza-Zamora JG, González J, Gómez-García A,López-Ortiz G. SARS-CoV-2 variants and clinicaloutcomes: A systematic review. Life 2022;12:170.https://doi.org/10.3390/life12020170.

  2. Tiecco G, Storti S, Degli Antoni M, Focà E,Castelli F, Quiros-Roldan E. Omicron geneticand clinical peculiarities that may overturnSARS-CoV-2 pandemic: A literature review. IntJ Mol Sci 2022;23. https://doi.org/10.3390/ijms23041987.

  3. Bahraini M, Dorgalaleh A. The impact ofSARS-CoV-2 infection on blood coagulationand fibrinolytic pathways: a review ofprothrombotic changes caused by COVID-19.Semin Thromb Hemost 2022;48:19-30. https://doi.org/10.1055/s-0041-1736166.

  4. Blomme S, Smets L, Van Ranst M, Boeckx N,Van Laer C. The influence of COVID-19 on routinehematological parameters of hospitalized patients.Acta Clin Belg 2022;77:241-246. https://doi.org/10.1080/17843286.2020.1814649.

  5. Dubey DB, Mishra S, Reddy HD, Rizvi A, AliW. Hematological and serum biochemistryparameters as a prognostic indicator of severallyill versus mild COVID-19 patients: A studyfrom tertiary hospital in North India. Clin EpidemiolGlob Health 2021;12:100806. https://doi.org/10.1016/j.cegh.2021.100806.

  6. Yang H, Xu Y, Li Z, Yan L, Wang J, Liao P. Theclinical implication of dynamic hematologicalparameters in COVID-19: A retrospectivestudy in Chongqing, China. Int J Gen Med2021;14:4073-4080. https://doi.org/10.2147/ijgm.S321292.

  7. Ghazanfari T, Salehi MR, Namaki S, ArabkheradmandJ, Rostamian A, RajabniaChenary M, et al. Interpretation of hematological,biochemical, and immunological findingsof COVID-19 disease: Biomarkers associatedwith severity and mortality. Iran J AllergyAsthma Immunol 2021;20:46-66. https://doi.org/10.18502/ijaai.v20i1.5412.

  8. Elkhalifa AME, Elderdery AY, Al Bataj IA,Tamomh AG, Alyami MM, Almakrami HA,et al. Hematological findings among COVID-19 patients attending King Khalid Hospitalat Najran, Kingdom of Saudi Arabia. BiomedRes Int 2022;2022:4620037. https://doi.org/10.1155/2022/4620037.

  9. Al-Saadi E, Abdulnabi MA. Hematologicalchanges associated with COVID-19 infection.J Clin Lab Anal 2022;36:e24064. https://doi.org/10.1002/jcla.24064.

  10. Suryawanshi SY, Priya S, Sinha SS, Soni S,Haidry N, Verma S, et al. Dynamic profile andclinical implications of hematological and immunologicalparameters in COVID-19 patients.A retrospective study. J Family Med Prim Care2021;10:2518-2523. https://doi.org/10.4103/jfmpc.jfmpc_2400_20.

  11. Taj S, Kashif A, Arzinda Fatima S, Imran S,Lone A, Ahmed Q. Role of hematological parametersin the stratification of COVID-19 diseaseseverity. Ann Med Surg (Lond) 2021;62:68-72.https://doi.org/10.1016/j.amsu.2020.12.035.

  12. Saurabh A, Dey B, Raphael V, Barman B, DevP, Tiewsoh I, et al. Evaluation of hematologicalparameters in predicting intensive care unitadmission in COVID-19 patients. SN ComprClin Med 2022;4:39. https://doi.org/10.1007/s42399-021-01115-8.

  13. Damiati LA, Bahlas S, Aljohaney A, BawazirY, Mustafa M, Denetiu I, et al. Implications ofSARS-CoV-2 infection on the clinical, hematological,and inflammatory parameters in COVID-19 patients: A retrospective cross-sectionalstudy. J Infect Public Health 2022;15:214-221.https://doi.org/10.1016/j.jiph.2021.12.013.

  14. Szklanna PB, Altaie H, Comer SP, Cullivan S,Kelliher S, Weiss L, et al. Routine hematologicalparameters may be predictors of COVID-19severity. Front Med (Lausanne) 2021;8:682843.https://doi.org/10.3389/fmed.2021.682843.

  15. Alkan G, Sert A, Emiroglu M, Tuter Oz SK, VatansevH. Evaluation of hematological parametersand inflammatory markers in children withCOVID-19. Ir J Med Sci 2021:1-9. https://doi.org/10.1007/s11845-021-02762-5.

  16. Ötiken-Arıkan K, Şahinkaya Ş, BöncüoğluE, Kıymet E, Cem E, Akaslan-Kara A, et al.Can hematological findings of COVID-19in pediatric patients guide physicians regardingclinical severity? Turk J Haematol2021;38:243-245. https://doi.org/10.4274/tjh.galenos.2021.2021.0157.

  17. Shokri P, Golmohammadi S, Noori M, NejadghaderiSA, Carson-Chahhoud K, SafiriS. The relationship between blood groups andrisk of infection with SARS-CoV-2 or developmentof severe outcomes: A review. Rev MedVirol 2022;32:e2247. https://doi.org/10.1002/rmv.2247.

  18. Saleh M, Alkofide A, Alshammari A, SiddiquiK, Owaidah T. Changes in hematological,clinical and laboratory parameters for childrenwith covid-19: Single-center experience.J Blood Med 2021;12:819-826. https://doi.org/10.2147/jbm.S321372.

  19. Bonaventura A, Vecchié A, Dagna L, MartinodK, Dixon DL, Van Tassell BW, et al. Endothelialdysfunction and immunothrombosisas key pathogenic mechanisms in COVID-19.Nat Rev Immunol 2021;21:319-329. https://doi.org/10.1038/s41577-021-00536-9.

  20. Abrignani MG, Murrone A, De Luca L, RonconL, Di Lenarda A, Valente S, et al. COVID-19,vaccines, and thrombotic events: A narrativereview. J Clin Med 2022;11. https://doi.org/10.3390/jcm11040948.

  21. Chen AT, Wang CY, Zhu WL, Chen W. Coagulationdisorders and thrombosis in COVID-19 patients and a possible mechanisminvolving endothelial cells: A review. Aging Dis2022;13:144-156. https://doi.org/10.14336/ad.2021.0704.

  22. Sbirkov Y, Dzharov V, Todorova K, HayrabedyanS, Sarafian V. Endothelial inflammation anddysfunction in COVID-19. Vasa 2022;51:62-70.https://doi.org/10.1024/0301-1526/a000991.

  23. Cryer MJ, Farhan S, Kaufmann CC, Jäger B,Garg A, Krishnan P, et al. Prothrombotic milieu,thrombotic events and prophylactic anticoagulationin hospitalized COVID-19 positivepatients: A review. Clin Appl Thromb Hemost2022;28:10760296221074353. https://doi.org/10.1177/10760296221074353.

  24. Sastry S, Cuomo F, Muthusamy J. COVID-19and thrombosis: The role of hemodynamics.Thromb Res 2022;212:51-57. https://doi.org/10.1016/j.thromres.2022.02.016.

  25. Iba T, Warkentin TE, Thachil J, Levi M, Levy JH.Proposal of the definition for COVID-19-associatedcoagulopathy. J Clin Med 2021;10:191.https://doi.org/10.3390/jcm10020191.

  26. Teimury A, Khameneh MT, Khaledi EM. Majorcoagulation disorders and parameters inCOVID-19 patients. Eur J Med Res 2022;27:25.https://doi.org/10.1186/s40001-022-00655-6.

  27. Ulanowska M, Olas B. Modulation of hemostasisin COVID-19; blood platelets may be importantpieces in the COVID-19 puzzle. Pathogens(Basel, Switzerland) 2021;10:370. https://doi.org/10.3390/pathogens10030370.

  28. Violi F, Pastori D, Cangemi R, Pignatelli P,Loffredo L. Hypercoagulation and antithrombotictreatment in coronavirus 2019: A newchallenge. Thromb Haemost 2020;120:949-956. https://doi.org/10.1055/s-0040-1710317.

  29. Guan W-J, Ni Z-Y, Hu Y, Liang W-H, Ou C-Q,He J-X, et al. Clinical characteristics of coronavirusdisease 2019 in China. N Engl J Med2020;382:1708-1720. https://doi.org/10.1056/NEJMoa2002032.

  30. La Torre G, Marte M, Massetti AP, Carli SM, RomanoF, Mastroianni CM, et al. The neutrophil/lymphocyte ratio as a prognostic factor in COVID-19 patients: a case-control study. Eur RevMed Pharmacol Sci 2022;26:1056-1064. https://doi.org/10.26355/eurrev_202202_28017.

  31. Castillo-Martínez D, Torres Z, Amezcua-Guerra LM, Pineda C. Are antiphospholipidantibodies just a common epiphenomenonor are they causative of immune-mediatedcoagulopathy in COVID-19? Clin Rheumatol2021;40:3015-3019. https://doi.org/10.1007/s10067-021-05724-5.

  32. Favaloro EJ, Henry BM, Lippi G. COVID-19 andantiphospholipid antibodies: Time for a realitycheck? Semin Thromb Hemost 2022;48:72-92.https://doi.org/10.1055/s-0041-1728832.

  33. Xiao M, Zhang Y, Zhang S, Qin X, Xia P,Cao W, et al. Antiphospholipid antibodies incritically ill patients with COVID-19. ArthritisRheumatol 2020;72:1998-2004. https://doi.org/10.1002/art.41425.

  34. Al-Ali D, Elshafeey A, Mushannen M, KawasH, Shafiq A, Mhaimeed N, et al. Cardiovascularand haematological events post COVID-19 vaccination: A systematic review. JCell Mol Med 2022;26:636-653. https://doi.org/10.1111/jcmm.17137.

  35. Klok FA, Pai M, Huisman MV, Makris M. Vaccine-induced immune thrombotic thrombocytopenia.Lancet Haematol 2022;9:e73-e80. https://doi.org/10.1016/s2352-3026(21)00306-9.

  36. Mohseni-Afshar Z, Babazadeh A, JanbakhshA, Afsharian M, Saleki K, Barary M, et al.Vaccine-induced immune thrombotic thrombocytopeniaafter vaccination against Covid-19:A clinical dilemma for clinicians and patients.Rev Med Virol 2022;32:e2273. https://doi.org/10.1002/rmv.2273.

  37. Iba T, Levy JH. Thrombosis and thrombocytopeniain COVID-19 and after COVID-19 vaccination.Trends Cardiovasc Med 2022. https://doi.org/10.1016/j.tcm.2022.02.008.

  38. Arepally GM, Ortel TL. Vaccine-induced immunethrombotic thrombocytopenia: what we knowand do not know. Blood 2021;138:293-298.https://doi.org/10.1182/blood.2021012152.

  39. Bussel JB, Connors JM, Cines DB, Dunbar CE,Michaelis LC, Baumann-Kreuziger L, et al.Vaccine-induced Immune thrombotic thrombocytopenia.Washington: American Societyof Hematology; 2022. Acceso 30 de marzo de2022. Disponible en https://www.hematology.org/covid-19/vaccine-induced-immune-thrombotic-thrombocytopenia.

  40. Ahmed SH, Shaikh TG, Waseem S, Qadir NA,Yousaf Z, Ullah I. Vaccine-induced thromboticthrombocytopenia following coronavirus vaccine:A narrative review. Ann Med Surg (Lond)2022;73:102988. https://doi.org/10.1016/j.amsu.2021.102988.

  41. Bilotta C, Perrone G, Adelfio V, SpatolaGF, Uzzo ML, Argo A, et al. COVID-19vaccine-related thrombosis: A systematic reviewand exploratory analysis. Front Immunol2021;12:729251. https://doi.org/10.3389/fimmu.2021.729251.

  42. Franchini M, Liumbruno GM, Pezzo M. COVID-19 vaccine-associated immune thrombosisand thrombocytopenia (VITT): Diagnosticand therapeutic recommendations for a newsyndrome. Eur J Haematol 2021;107:173-180.https://doi.org/10.1111/ejh.13665.

  43. Calcaterra G, Bassareo PP, Barilla F, RomeoF, Mehta JL. Concerning the unexpectedprothrombotic state following some coronavirusdisease 2019 vaccines. J CardiovascMed (Hagerstown) 2022;23:71-74. https://doi.org/10.2459/jcm.0000000000001232.

  44. Matar RH, Than CA, Nakanishi H, Daniel RS,Smayra K, Sim BL, et al. Outcomes of patientswith thromboembolic events following coronavirusdisease 2019 AstraZeneca vaccination:a systematic review and meta-analysis. BloodCoagul Fibrinolysis 2022;33:90-112. https://doi.org/10.1097/mbc.0000000000001113.

  45. Cauchi M, Ball H, Ben-Shlomo Y, RobertsonN. Interpretation of vaccine associated neurologicaladverse events: a methodological andhistorical review. J Neurol 2022;269:493-503.https://doi.org/10.1007/s00415-021-10747-8.

  46. Afshar ZM, Barary M, Babazadeh A, HosseinzadehR, Alijanpour A, Miri SR, et al. SARSCoV-2-related and Covid-19 vaccine-inducedthromboembolic events: A comparative review.Rev Med Virol 2022:e2327. https://doi.org/10.1002/rmv.2327.

  47. Lippi G, Favaloro EJ. Cerebral venousthrombosis developing after COVID-19 vaccination:VITT, VATT, TTS, and more. SeminThromb Hemost 2022;48:8-14. https://doi.org/10.1055/s-0041-1736168.

  48. Sharifian-Dorche M, Bahmanyar M, Sharifian-Dorche A, Mohammadi P, Nomovi M, MowlaA. Vaccine-induced immune thrombotic thrombocytopeniaand cerebral venous sinus thrombosispost COVID-19 vaccination; a systematicreview. J Neurol Sci 2021;428:117607. https://doi.org/10.1016/j.jns.2021.117607.

  49. Uzun G, Pelzl L, Singh A, Bakchoul T. Immunemediatedplatelet activation in COVID-19 andvaccine-induced immune thrombotic thrombocytopenia.Front Immunol 2022;13:837629.https://doi.org/10.3389/fimmu.2022.837629.

  50. Kashir J, Ambia AR, Shafqat A, Sajid MR,AlKattan K, Yaqinuddin A. Scientific premise forthe involvement of neutrophil extracellular traps(NETs) in vaccine-induced thrombotic thrombocytopenia(VITT). J Leukoc Biol 2022;111:725-734.https://doi.org/10.1002/jlb.5covr0621-320rr.

  51. Simka M. Asociación de las vacunas frente a laCOVID-19 basadas en vectores de adenovirus ytrombosis del seno venoso cerebral: ¿guardanrelación estos episodios con la formación detrampas extracelulares de neutrófilos? Vacunas2022;23:564-567. https://doi.org/10.1016/j.vacun.2021.12.002.

  52. Kheyrandish S, Rastgar A, Arab-Zozani M,Sarab GA. Portal vein thrombosis might developby COVID-19 infection or vaccination: Asystematic review of case-report studies. FrontMed 2021;8:794599. https://doi.org/10.3389/fmed.2021.794599.

  53. de Gregorio C, Colarusso L, Calcaterra G,Bassareo PP, Ieni A, Mazzeo AT, et al. Cerebralvenous sinus thrombosis following COVID-19 vaccination: Analysis of 552 worldwidecases. Vaccines (Basel) 2022;10:232. https://doi.org/10.3390/vaccines10020232.

  54. Elberry MH, Abdelgawad HAH, HamdallahA, Abdella WS, Ahmed AS, Ghaith HS, et al.A systematic review of vaccine-induced thromboticthrombocytopenia in individuals whoreceived COVID-19 adenoviral-vector-basedvaccines. J Thromb Thrombolysis 2022:1-26.https://doi.org/10.1007/s11239-021-02626-w.

  55. Finsterer J. Neurological side effects ofSARS-CoV-2 vaccinations. Acta Neurol Scand2022;145:5-9. https://doi.org/10.1111/ane.13550.

  56. Hafeez MU, Ikram M, Shafiq Z, Sarfraz A,Sarfraz Z, Jaiswal V, et al. COVID-19 vaccineassociatedthrombosis with thrombocytopeniasyndrome (TTS): A systematic review andpost hoc analysis. Clin Appl Thromb Hemost2021;27:10760296211048815. https://doi.org/10.1177/10760296211048815.

  57. Waqar U, Ahmed S, Gardezi S, Tahir MS,Abidin ZU, Hussain A, et al. Thrombosiswith thrombocytopenia syndrome afteradministration of AZD1222 or Ad26.COV2.S vaccine for COVID-19: A systematicreview. Clin Appl Thromb Hemost2021;27:10760296211068487. https://doi.org/10.1177/10760296211068487.

  58. Favaloro EJ, Pasalic L, Lippi G. Review andevolution of guidelines for diagnosis of COVID-19 vaccine induced thrombotic thrombocytopenia(VITT). Clin Chem Lab Med2022;60:7-17. https://doi.org/10.1515/cclm-2021-1039.




2020     |     www.medigraphic.com